Background: Lung cancer is the leading cause of cancer death worldwide. Small cell lung cancer (SCLC) is a malignancy with multiplex toxin-associated mutations, which accounts for about 15% of all the types of lung cancers. Overall, it remains a clinical challenge with extremely aggressive behavior of early systemic spreading. No effective target therapies and protein biomarkers are available in the treatment of SCLC and the association between gene mutations and SCLC still remains unclear. It makes an urgent need for detection of novel biomarkers in this highly lethal neuroendocrine type of cancer. Method: We assessed the four protein biomarkers and performed 303 cancer driver genes to investigate the mutation profiles of 32 FFPE tissues derived from Chinese SCLC patients using next generation sequencing. Results: Amongst the 32 FFPE samples, mutant genes were observed in all the patients of SCLC (32/32, 100%). TP53 mutations were the most prevalent (19/ 32; 59.38%), followed by RB1 (11/32; 34.38%), KMT2D (8/32; 25%), BRCA1 (6/32; 18.75%), LRRK2 (6/32; 18.75%), and ARID2 (6/32; 18.75%). Notably, there was relatively high mutation hotspot (6.25%, 2/32) of the p.P278S and p.W516X mutations in TP53 and RB1, respectively. Overall, the six of the most frequent mutations were identified in patients with SCLC including three well-known mutant genes (TP53, RB1 and KMT2D) and three rare genes (BRCA1, LRRK2 and ARID2) not previously reported in Chinese patients with SCLC. Conclusion: Based on our findings, we propose that these oncogenic mutations might serve as potential biomarkers and provide clinicians with candidate therapeutic targets for Chinese SCLC patients. Keywords: oncogenic mutations, small cell lung cancer, protein biomarkers, formalin-fixed paraffin-embedded tissues P041 Different Recurrence Models in Lung Cancer Patients Between "aBVA method" and "VAB method" During Right Upper Lobectomy Background: As concluded recently, compared with "VAB method" (dissecting pulmonary vessels first, followed by the bronchus), "aBVA method" (dissecting the posterior ascending arterial branch first, followed by the bronchus and vessels) during right upper lobectomy (RUL) would promote surgical feasibility and postoperative recovery for lung cancer patients. This study compared their recurrence models. Method: Consecutive lung cancer patients undergoing RUL were grouped into aBVA and VAB cohorts. The recurrence models in patients with disease recurrence between two cohorts were compared by Chi-
Background: Lung cancer is the leading cause of cancer death worldwide. Small cell lung cancer (SCLC) is a malignancy with multiplex toxin-associated mutations, which accounts for about 15% of all the types of lung cancers. Overall, it remains a clinical challenge with extremely aggressive behavior of early systemic spreading. No effective target therapies and protein biomarkers are available in the treatment of SCLC and the association between gene mutations and SCLC still remains unclear. It makes an urgent need for detection of novel biomarkers in this highly lethal neuroendocrine type of cancer. Method: We assessed the four protein biomarkers and performed 303 cancer driver genes to investigate the mutation profiles of 32 FFPE tissues derived from Chinese SCLC patients using next generation sequencing. Results: Amongst the 32 FFPE samples, mutant genes were observed in all the patients of SCLC (32/32, 100%). TP53 mutations were the most prevalent (19/ 32; 59.38%), followed by RB1 (11/32; 34.38%), KMT2D (8/32; 25%), BRCA1 (6/32; 18.75%), LRRK2 (6/32; 18.75%), and ARID2 (6/32; 18.75%). Notably, there was relatively high mutation hotspot (6.25%, 2/32) of the p.P278S and p.W516X mutations in TP53 and RB1, respectively. Overall, the six of the most frequent mutations were identified in patients with SCLC including three well-known mutant genes (TP53, RB1 and KMT2D) and three rare genes (BRCA1, LRRK2 and ARID2) not previously reported in Chinese patients with SCLC. Conclusion: Based on our findings, we propose that these oncogenic mutations might serve as potential biomarkers and provide clinicians with candidate therapeutic targets for Chinese SCLC patients. Keywords: oncogenic mutations, small cell lung cancer, protein biomarkers, formalin-fixed paraffin-embedded tissues P041 Different Recurrence Models in Lung Cancer Patients Between "aBVA method" and "VAB method" During Right Upper Lobectomy Background: As concluded recently, compared with "VAB method" (dissecting pulmonary vessels first, followed by the bronchus), "aBVA method" (dissecting the posterior ascending arterial branch first, followed by the bronchus and vessels) during right upper lobectomy (RUL) would promote surgical feasibility and postoperative recovery for lung cancer patients. This study compared their recurrence models. Method: Consecutive lung cancer patients undergoing RUL were grouped into aBVA and VAB cohorts. The recurrence models in patients with disease recurrence between two cohorts were compared by Chisquare test and Fisher's exact test after propensity score matching (PSM). Results: 297 patients were selected (167 in the aBVA cohort, and 130 in the VAB cohort). Before PSM, average operation time, estimated blood loss, TNM stage, sleeve lobectomy, the number of operating holes, conversion to thoracotomy, whether arteries and veins were co-resected, histological subtype, atelectasis requires fiberoptic suction, myocardial infarction, neurologic events, pulmonary infection were not balanced (P<0.05) between two cohorts. After PSM (caliper¼0.05), 89 pairs of patients were successfully matched, and these 12 characters were all balanced (P>0.05). During the follow-up period, 56 (31.5%) patients of the above 89 pairs experienced disease recurrence: 26 in the aBVA cohort and 30 in the VAB cohort (P ¼ 0.783). Taking recurrence models into consideration, intrathoracic local recurrence (16.9% vs. 22.5%, P > 0.05) and distant metastases intrathoracic local recurrence (10.1% vs. 9.0%, P > 0.05) were comparable in both cohorts. Conclusion: "aBVA method" tends to control local disease recurrences better, whereas "VAB method" tends to control distant recurrences better during right upper lobectomy for lung cancer patients. Background: Lung cancer has been recognized as the leading cause of cancer-related deaths throughout the world. Due to failing early diagnosis and severe chemotherapy response, the 5-year survival rate of lung cancer has been staggering at about 15%. Therefore, searching for new biomarkers for metastatic progression of nonsmall cell lung cancer (NSCLC) is urgent. Recent studies have demonstrated the association between long non-coding RNA (LncRNA) and multiple cancer types. LincRNA00494, a novel long intergenic non-protein coding gene, its function has not been fully expounded. In the present study, we found that LincRNA00494 was down-regulated in non-small cell lung cancer tissue compared with the corresponding adjacent non-tumor tissue. Our findings might reveal the underlying mechanism by which LincRNA00494 aberrant expression conferred NSCLC tumorigenesis. Method: We compared the expression level of LINCRNA00494 by RT-PCR in 163 patients with non-small cell lung cancer with the tumor tissue and the normal tissue of distant cancer. We compared the association between LINCRNA00494 and SRCIN1 mRNA in tumor tissues by RT-PCR. Plasmid knockdown and overexpression of LINCRNA00494 were used to compare the effects of changes in LINCRNA00494 expression on SRCIN1 mRNA. To verify the role of miR-150-3p in NSCLC cells, we cloned the 3' UTR of SRCIN1 and LincRNA00494 into psiCHECK2
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